Jaideep Dudani

Private Equity Investor chez Monograph Capital Advisors (UK) LLP

Profil

Jaideep Dudani is a Portfolio Principal at Monograph and leads Portfolio Development at Monograph’s portfolio company, Hi-Bio.
He was most recently at Relay Therapeutics, a precision medicine company focused on oncology and rare genetic diseases, where he played a cross-functional role in R&D and strategy and business development.
Before that, Jaideep was the first associate at Vida Ventures, and was involved in several of Vida’s investments, including Allogene Therapeutics (which held its initial public offering on the NASDAQ Global Select Market in 2018), Asklepios BioPharmaceutical (which was acquired by Bayer AG in 2020), Oyster Point Pharma (which held its initial public offering on the NASDAQ Global Select Market in 2019), and Pionyr Immunotherapeutics (which was acquired by Gilead Sciences, Inc. in 2020).
He completed his PhD at MIT in Biological Engineering, and holds a BS in Bioengineering from UCLA.

Postes actifs de Jaideep Dudani

Sociétés	Poste	Début
Monograph Capital Advisors (UK) LLP	Private Equity Investor	01/07/2021

Anciens postes connus de Jaideep Dudani

Sociétés	Poste	Fin
RELAY THERAPEUTICS, INC.	Corporate Officer/Principal	30/06/2021
Glympse Bio, Inc.	Consultant / Advisor	31/03/2018

Formation de Jaideep Dudani

Massachusetts Institute of Technology	Doctorate Degree
University of California, Los Angeles	Undergraduate Degree